FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2302-2304 May 27, 2004 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Two shadows have recently been cast over the exciting field of gene therapy. One was cast by the unfortunate death of an 18-year-old man at the University of Pennsylvania in 1999.¹ The patient was part of a trial in which an adenovirus containing a gene for ornithine transcarbamylase was infused into patients with partial deficiencies of the enzyme. The death highlighted the potential dangers of the direct administration of adenoviruses and, perhaps, other viruses to patients. The second shadow was cast by a clinical trial involving children with X-linked severe combined immunodeficiency (SCID).² The trial had an added measure of . . . [Full Text of this Article]

Source Information

From the Center for Gene Therapy, Tulane University Health Sciences Center, New Orleans.

This article has been cited by other articles:

• Ishikawa, F., Shimazu, H., Shultz, L. D., Fukata, M., Nakamura, R., Lyons, B., Shimoda, K., Shimoda, S., Kanemaru, T., Nakamura, K.-i., Ito, H., Kaji, Y., Perry, A. C.F., Harada, M. (2006). Purified human hematopoietic stem cells contribute to the generation of cardiomyocytes through cell fusion. FASEB J. 20: 950-952 [Abstract] [Full Text]